Releaf Partners with Glass Pharms to Improve Medical Cannabis Supply
Releaf, one of the UK's fastest-growing medical marijuana providers, has announced an exciting partnership with Glass Pharms, a domestic producer of medical cannabis. This collaboration enables Glass Pharms to supply Releaf with a substantial 145kg (320 pounds) of premium, medical-grade cannabis, significantly enhancing the company’s capacity to serve its patients.
Significance of the Partnership
This milestone partnership signifies a major advancement for Releaf and the broader UK medical cannabis sector. As stated by Tim Kirby, managing director of Releaf, this agreement not only sets a new record in UK cannabis dealings but also highlights the increasing recognition of medical cannabis as a viable healthcare solution. This development sets a new benchmark for reliability, ensuring Releaf can meet patient demand effectively while enhancing care standards.
Meeting Growing Patient Demand
Releaf anticipates that within the next year, its patient base will surpass the current UK sector size, estimated at around 45,000 patients. The company revealed it is already serving more than 100 patients daily, positioning itself to become the leading medical marijuana provider in the UK in the next six months.
Enhancing the Supply Chain
The collaboration between Releaf and Glass Pharms ensures a stable and consistent supply chain of high-quality medical cannabis. This is crucial in addressing the prescription reliability issues that have been detrimental to the growth of many businesses within the industry.
Innovative Cultivation Techniques
Glass Pharms stands out as one of the original commercial growers of high-THC cannabis for medical use, utilizing advanced AI and robotic automation in the cultivation process. This modern approach guarantees consistent product quality while maintaining a carbon-negative operational footprint, making it a pioneer in sustainable practices within the cannabis field.
Shifting Trends in Medical Marijuana Prescriptions
The private prescription of medical marijuana in the UK has seen remarkable growth, doubling each year since 2021, according to data from the National Health Service Business Services Authority. Specifically, the number of private prescriptions for unlicensed cannabis-based medicines climbed from 6,137 in September 2021 to 22,431 by September 2023.
Challenges with NHS Access
While accessing medical marijuana through the National Health Service (NHS) is an option, this occurs infrequently and predominantly in severe cases such as epilepsy or chemotherapy-induced nausea. Because medical marijuana is not readily available via the NHS, families often experience challenges in affording necessary medications for their loved ones.
Looking Ahead
The partnership between Releaf and Glass Pharms is anticipated to play a crucial role in addressing existing supply challenges, ensuring that more patients have access to consistent, high-quality medical cannabis. As the industry moves forward, such alliances will be vital in shaping the future of medical marijuana in the UK, promising a healthier horizon for those in need.
Frequently Asked Questions
What is the partnership between Releaf and Glass Pharms?
The partnership aims to secure a reliable supply of high-quality medical cannabis, with Glass Pharms supplying Releaf 145kg of medical-grade product.
How does this collaboration impact patients?
This collaboration ensures that patients have a consistent and high-quality source of medical cannabis, which enhances reliability in prescriptions.
What growth does Releaf anticipate?
Releaf expects its patient base to grow beyond the current 45,000 patients in the UK over the next 12 months.
Why is Glass Pharms considered innovative?
Glass Pharms employs AI and robotic automation in cannabis cultivation, ensuring high product quality and promoting sustainable practices.
What challenges do families face regarding medical marijuana?
Families often encounter difficulties in affording medical marijuana due to its limited availability through the NHS, making private prescriptions necessary.
